Morningstar® Stock Report™

AbbVie Inc ABBV

Letzte Unternehmensnews

DatumZeitQuelleTitel
Previous Stories...
14.05.202416:10ZACKSAbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
14.05.202413:00ZACKSInvestors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
13.05.202413:10ZACKSImprove Your Retirement Income with These 3 Top-Ranked Dividend Stocks
13.05.202412:47DJNM*DJ AbbVie: Gilgamesh Will Receive Upfront Payment of $65M From Co. and Eligible to Receive Up to $1.95B in Option Fees and Milestones, as Well as Tiered Royalties From Mid-Single to Low-Double Digits on Net Sales >ABBV
13.05.202412:46DJNM*DJ AbbVie: Will Lead Development and Commercialization Activities >ABBV
13.05.202412:45DJNM*DJ AbbVie: Collaboration Will Leverage Co's Expertise in Psychiatry and Gilgamesh's Innovative Research Platform to Discover Novel Neuroplastogens >ABBV
13.05.202412:44DJNM*DJ AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
13.05.202412:39DJNMPress Release: AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
13.05.202412:39DJNMAbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
13.05.202412:39PRNPREMAbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
10.05.202415:16ZACKSIronwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
09.05.202416:14ZACKSTEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
08.05.202422:06DJNM*DJ AbbVie Inc.: Exec Chmn Richard Gonzalez Annual Base Salary $1.5M >ABBV
08.05.202422:06DJNM*DJ AbbVie Inc.: CEO Robert Michael Annual Base Salary $1.7M >ABBV
08.05.202412:02DJNM*DJ AbbVie: QULIPTA Approved by Health Canada for Preventive Treatment of Chronic Migraine in Adults >ABBV
08.05.202412:00DJNMQULIPTA (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
08.05.202412:00CANADANWQULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
08.05.202412:00DJNMPress Release: QULIPTA (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
07.05.202420:30DJNMDJ Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com
06.05.202413:10ZACKS3 Top Dividend Stocks to Maximize Your Retirement Income